Gsk Share Discussion Threads

[toffeeman] 12/11/2018 14:13

Hovvering over the buy button but concerned it might close below the neckline - where's me cojones?

[ny boy] 12/11/2018 08:16

RHS inverted h&s breakout

[tradermichael] 11/11/2018 08:06

First single inhaler triple therapy to be specifically indicated for COPD patients not adequately treated with dual bronchodilation

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has authorised an expanded label for once-daily Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI217;), recognising its effect on exacerbations and making it the first single inhaler triple therapy indicated for patients with moderate to severe chronic obstructive pulmonary disease (COPD) not adequately treated with dual bronchodilation or with an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA).

[tradermichael] 09/11/2018 15:41

Looks like your prediction is being matched, NY B. Will the price hit resistance before an xd drop?

[ny boy] 09/11/2018 15:38

Hey guys the inverted h&s is playing out so well, rhs breakout, back tested 1553 this morning and off to the races on defensive qualities etc GLA

[tradermichael] 09/11/2018 13:18

First, get through the regulators!

[grahamburn] 09/11/2018 10:59

From today's Times Business News:

___________________________

Duo to make generic version of Glaxo treatment
Alex Ralph
November 9 2018

Two UK-listed drugs companies have launched plans to develop a copycat version of Glaxosmithkline̵7;s lucrative respiratory portfolio.

Hikma Pharmaceuticals and Vectura Group have signed an agreement to commercialise generic versions of Glaxo’s Ellipta products as they target the potential $5.5 billion sales forecast for the products by 2024. The tie-up marks a deepening of the relationship between Hikma and Vectura, who are attempting to launch a version of Glaxo’s successful Advair inhaler.

Hikma was founded in Jordan in 1978 and spans more than 50 countries, selling generic, branded and injectable products. It appointed Siggi Olafsson, the former boss of Teva, an Israeli rival, as chief executive this year to revive the company, which has struggled with delays in launching a generic Advair and had repeatedly downgraded its financial forecasts, triggering its exit from the FTSE 100.
Vectura, based in Chippenham, Wiltshire, is a respiratory specialist that has partnerships with several big pharma companies, including Glaxo.

Following conversations with the US Food and Drug Administration, the duo have agreed to develop and commercialise at least three of Glaxo’s portfolio products, with the Breo Ellipta being prioritised.

Hikma will make an upfront payment of $15 million to Vectura, which will fund the initial development. Hikma will be responsible for clinical development, regulatory submission and commercialisation and will make a $5 million milestone payment once the first product is transferred to Hikma’s manufacturing site. Hikma will then make milestone payments of up to $75 million and, if regulatory approval is granted, it will pay a share of profits of up to a “mid-teen percentage” for each product. Vectura will contribute up to $70 million in deferred payments towards Hikma’s development activities.

Hikma’s shares closed up 5.6 per cent at £20.25. The shares in Glaxosmithkline closed up 1.9 per cent at £15.60¼.

[tradermichael] 09/11/2018 08:30

If you invested £100,000 in GSK and compounded the dividends (say 5%) by re-investing in GSK shares, after 14 years your holding would be worth £200,000. Not a bad value return, I think, irrespective of any change in the share price.

No breakup, I say.

[porsche1945] 08/11/2018 20:54

Wow, GSK never fails to disapoint, just looking at share graph for last ten years, pitiful, no value created, something seriously wrong with it made worse by the now forging ahead of Astra (right after Woodford sold them, he has no luck) A break up of this might upset the income seekers but real money is made through capital appreciation, this needs breaking up selling off and value created for shareholders, the headcount is way too high as well, need to start shedding jobs and fast, cut costs, drive anything that will go to the bottom line, these should be twenty quid a share, they kind of relect the ftse index in general, basically gone nowhere in twenty years, hopeless, especially as every other index has doubled or tripled.

[ny boy] 08/11/2018 17:09

Up & down and up, it’s what makes the markets, see what tomorrow brings but the breakout from the inverted h&s seems to have started, a close below 1550 tomorrow negates this, today’s close is a good sign but you never know with these stocks, best just keep a core holding for a decent annual divi and have a few trades for pocket money.

[abdullla] 08/11/2018 16:08

GSK did go up 50p on results but profit takers pulled it down.

[tradermichael] 08/11/2018 15:54

But why GSK went down on good results while AZN up over 5% on poor results and a day when GSK only up 2%??

[abdullla] 08/11/2018 15:45

Maybe Trump changed his mind on price wars with pharmaceuticals.

[jadeticl3] 08/11/2018 15:26

GSK is having a good day so far, up 2%, but AZN, whose results today, according to headlines are not impressive, and yet the shares have risen over 5% to a 5 year high.
This is puzzling!

[ny boy] 08/11/2018 13:44

As hoped for but as a precaution banking 50% @ 1554p of a recent trade from 1480’s, leave other holdings for divi

[ny boy] 08/11/2018 12:38

Clear to go if we can clear 1552p approx

[alphorn] 08/11/2018 11:04

Hikma (+ Vectura) will develop, using Vectura's proprietary inhaler device, a generic version of GlaxoSmithKline PLC's Ellipta portfolio.
This includes the development of up to five GSK respiratory medicine generics, with at least three of the portfolio products agreed.
Ellipta inhalers are a specialised type of inhaler which use a dry powder and are used to treat asthma and chronic obstructive pulmonary disease.
Net US sales for Ellipta products in the US are expected to be USD4 billion by 2024 and approximately USD5.5 billion globally.

[ny boy] 08/11/2018 08:16

We should be at the US close around 1550pish

[ny boy] 07/11/2018 20:08

TM

It shows clearly in the long term chart in the header, US markets are back on a tear, this could well play out, worth watching.

Ex divi buyers are coming in too, could get a substantive move higher.GLA

[tradermichael] 07/11/2018 19:06

Love your chartism, NY B

[ny boy] 07/11/2018 16:37

Major inverted h&s starting to play out, the rhs developing into what could be a biggie upside move at least to test 1620p this quarter!

[ny boy] 07/11/2018 16:08

1540p resistance
1620p resistance

Looking good for a decent move higher as divi players move in

[ny boy] 07/11/2018 13:30

Popped 10p higher in last hour, someone likes, hopefully a big boost state side, off to check chart s/r levels, ex div Thursday week